Subscribe
29 April 2025FeaturesAfricaOlusola Tunmise-Ajani

Commercialising genomic tech in Nigeria

Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025   Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.
Europe
European court upholds 10x patent after Nanostring appealed injunction
20 March 2025   New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial molecular imaging products.
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.


Editor's picks

Why US patent reform is ‘essential’ for US economic prosperity and security
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

Editor's picks

Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025

More on this story

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025   Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.
Europe
European court upholds 10x patent after Nanostring appealed injunction
20 March 2025   New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial molecular imaging products.
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.

More on this story

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025   Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.
Europe
European court upholds 10x patent after Nanostring appealed injunction
20 March 2025   New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial molecular imaging products.
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.

More features

Why US patent reform is ‘essential’ for US economic prosperity and security
Medical company sees $452m trade secrets award cut by 87%
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
How pharma should prep for the six-bill avalanche from Congress
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist